Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Almirall ( (ES:ALM) ) just unveiled an announcement.
Almirall has released its 2025 Annual Corporate Governance Report, prepared in a free format authorized by Spain’s securities regulator, the CNMV, while preserving references to the official structure. The report aims to enhance clarity and transparency for stakeholders by using a narrative approach and includes the required Statistical Annex.
The document covers key governance areas such as ownership structure, the General Meeting, administrative bodies, related-party and intragroup transactions, and risk control and management systems, including those for financial reporting. By detailing its degree of compliance with corporate governance recommendations and highlighting other relevant information, Almirall reinforces its commitment to robust oversight and best practices in corporate governance.
The most recent analyst rating on (ES:ALM) stock is a Hold with a EUR14.00 price target. To see the full list of analyst forecasts on Almirall stock, see the ES:ALM Stock Forecast page.
More about Almirall
Almirall, S.A. is a Spanish pharmaceutical company based in Barcelona, operating in the healthcare industry. The company focuses on developing and marketing medicines, with an emphasis on transparency and regulatory compliance in its corporate governance and reporting practices.
Average Trading Volume: 200,021
Technical Sentiment Signal: Buy
Current Market Cap: €2.97B
For detailed information about ALM stock, go to TipRanks’ Stock Analysis page.